North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.510

-3.8%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don W Stone who wrote (60)	11/4/1996 7:19:00 PM
From: Rick Strange	of 82

I called a member of the staff of the FDA Vaccines and Related Biological Products Advisory Committee and asked for a clarification of last Tuesdays meeting to consider NVX's application to market its acellular pertussis vaccine for the primary three-dose vaccination series given at 2, 4, 6 moth of age. First of all I was informed that there was no panel vote. They read me a one paragraph release that stated that the panel determined that a four dose series given at 2,4,6, and 15 month was required to achieve 72% effective rate as reported in the Swedish trial. The statement went on to say that additional data was required for both the forth and fifth dose series. Sturza's Medical Investment Letter 10/31/96 f.253 was correct on these issues as well as all of the other material facts stated regarding the meeting. As I have stated before, I am short the stock. Rather than try to paint me with the same broad brush of character assination that you apply to anyone that feels a stock is overvalued I invite you to check the FACTS for your self. The Advisory Committee telephone # is (301)827-0314.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next